Di Virgilio, Francesco
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG 13025, IG 18581, IG 22883)
Ministero dell’Istruzione, dell’Università e della Ricerca (2017YTNWC)
Università degli Studi di Ferrara
Article History
Received: 30 August 2020
Accepted: 15 September 2020
First Online: 4 October 2020
Compliance with ethical standards
:
: FDV is a member of the Scientific Advisory Board of Biosceptre Ltd., a UK-based Biotech involved in the development of P2X7-targeted therapeutic antibodies.
: This article does not contain any studies with human participants or animals performed by any of the authors.